Novel treatments in acute myeloid leukemia

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 4, 2011, Pages 333-334

  Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CLOFARABINE; CPX 351; CYTARABINE; DAUNORUBICIN; IDARUBICIN; LENALIDOMIDE; LIPOSOMAL CYTARABINE PLUS DAUNORUBICIN; QUIZARTINIB; RETINOIC ACID; SORAFENIB; TOSEDOSTAT; UNCLASSIFIED DRUG; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY;

EID: 79955711627     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. American Cancer Society. What are the key statistics about acute myeloid leukemia? http://www.cancer.org/Cancer/Leukemia-AcuteMyeloidAML/Detailed-Guide/leukemia-acute-myeloid-myelogenous-key-statistics.
2. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010;28:4919-4925.
3. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96:62-68.
4. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010;28:2389-2395.
5. ClinicalTrials.gov. Decitabine maintenance in elderly acute myeloid leukemia patients. http://www.clinicaltrials.gov/ct2/show/NCT01149408?term=decitabine+aml+elderly&rank=1. Identifier: NCT01149408.
6. ClinicalTrials.gov. A study of clofarabine and cytarabine for older patients with relapsed or refractory acute myelogenous leukemia (AML)(CLASSIC I). http://www.clinicaltrials.gov/ct2/show/NCT00317642?term=aml+cytarabine+relapsed+clofarabine&rank=1. Identifier: NCT00317642.
7. Cortes J, Foran J, Ghirdaladze D, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. Blood (ASH Annual Meeting Abstracts). 2009;114(22): Abstract 636
8. Pratz KW, Cho E, Karp J, et al. Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol. 2009;27:15s. Abstract 7065.
9. Wiernik PH. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol. 2010;8:429-436.